48,536
edits
Difference between revisions of "Serous carcinoma of the endometrium"
Jump to navigation
Jump to search
Serous carcinoma of the endometrium (view source)
Revision as of 15:39, 21 May 2014
, 15:39, 21 May 2014+SO
(+SO) |
|||
| Line 82: | Line 82: | ||
*p16 +ve in tubal metaplasia.<ref name=pmid17429140>{{Cite journal | last1 = Horree | first1 = N. | last2 = Heintz | first2 = AP. | last3 = Sie-Go | first3 = DM. | last4 = van Diest | first4 = PJ. | title = p16 is consistently expressed in endometrial tubal metaplasia. | journal = Cell Oncol | volume = 29 | issue = 1 | pages = 37-45 | month = | year = 2007 | doi = | PMID = 17429140 }}</ref> | *p16 +ve in tubal metaplasia.<ref name=pmid17429140>{{Cite journal | last1 = Horree | first1 = N. | last2 = Heintz | first2 = AP. | last3 = Sie-Go | first3 = DM. | last4 = van Diest | first4 = PJ. | title = p16 is consistently expressed in endometrial tubal metaplasia. | journal = Cell Oncol | volume = 29 | issue = 1 | pages = 37-45 | month = | year = 2007 | doi = | PMID = 17429140 }}</ref> | ||
*WT1 usu. -ve -- useful to differentiate from [[ovarian serous carcinoma]].<ref name=pmid21993272>{{Cite journal | last1 = Bárcena | first1 = C. | last2 = Oliva | first2 = E. | title = WT1 expression in the female genital tract. | journal = Adv Anat Pathol | volume = 18 | issue = 6 | pages = 454-65 | month = Nov | year = 2011 | doi = 10.1097/PAP.0b013e318234aaed | PMID = 21993272 }}</ref> | *WT1 usu. -ve -- useful to differentiate from [[ovarian serous carcinoma]].<ref name=pmid21993272>{{Cite journal | last1 = Bárcena | first1 = C. | last2 = Oliva | first2 = E. | title = WT1 expression in the female genital tract. | journal = Adv Anat Pathol | volume = 18 | issue = 6 | pages = 454-65 | month = Nov | year = 2011 | doi = 10.1097/PAP.0b013e318234aaed | PMID = 21993272 }}</ref> | ||
==Sign out== | |||
<pre> | |||
ENDOMETRIUM, BIOPSY: | |||
- SEROUS CARCINOMA, HIGH-GRADE. | |||
COMMENT: | |||
The tumour stains as follows: | |||
POSITIVE: p16 (strong, diffuse), p53 (strong >85% of tumour). | |||
NEGATIVE: ER, PR. | |||
PROLIFERATION (Ki-67): 80% of the tumour. | |||
</pre> | |||
==See also== | ==See also== | ||